Please login to the form below

Not currently logged in
Email:
Password:

Ultragenyx

This page shows the latest Ultragenyx news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Ultragenyx gains EU approval for rare disease drug Mepsevii. Ultragenyx has gained EU approval for Mepsevii in the EU, the first treatment approved in Europe for Mucopolysaccharidosis VII (MPS VII). ... Kakkis, M.D., Ph.D., CEO and President of Ultragenyx

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    The research collaboration between Arcturus Therapeutics and Ultragenyx Pharmaceutical covers the discovery and development of mRNA therapeutics to certain rare disease targets using the Arcturus UNA Oligomer chemistry and LUNAR nanoparticle

  • Pharma deals during January 2013 Pharma deals during January 2013

    Deal Type. Comments. Baylor Research Institute. Ultragenyx. Collaboration. Triheptanoin UX 007 in rare and ultra-rare diseases. ... For example, Ultragenyx has in-licensed triheptanoin for long-chain fatty acid oxidation disorders from the Baylor

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Genentech’s Sunil Agarwal joins rare disease firm Genentech’s Sunil Agarwal joins rare disease firm

    Genentech’ s Sunil Agarwal joins rare disease firm. He will serve as chief medical officer at Ultragenyx. ... Dr Sunil Agarwal has left his senior role at Genentech to join rare disease specialist Ultragenyx Pharmaceutical as its chief medical officer.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics